Emergent nabs US government contract of up to $235.8M for anthrax vaccine
Emergent BioSolutions has been awarded a contract worth up to $235.8 million by the US Department of Defense to supply the only FDA-approved anthrax vaccine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
